Evidence map›Paper›PMID 41872153›Full record

ArticleCell death & disease2026

HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes.

Genaro R Villa, Paolo Alimonti, Joseph S Toker, Raziye Piranlioglu, Mikayla A Karkoski, Debora Mazzetti, Reda Ben Mrid, Sara El Guendouzi, Alexa Lauinger, Andrew N Chiocca and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Genaro R Villa *Harvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9461-2291
Paolo Alimonti *Harvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0009-0009-8359-9314
Joseph S TokerHarvard Medical School, Boston, MA, USA.
Raziye PiranliogluHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2450-3887
Mikayla A KarkoskiHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Debora MazzettiHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Reda Ben MridFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.ORCID http://orcid.org/0000-0001-6342-7405
Sara El GuendouziFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
Alexa LauingerHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Andrew N ChioccaHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rachid El FatimyFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
E Antonio ChioccaHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5183-1670
Marco MineoHarvey W. Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. mmineo@bwh.harvard.edu.ORCID http://orcid.org/0000-0001-7608-4579

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM144273
6 · The paper itself

Abstract

Although glioblastoma (GBM) harbors multiple genetic abnormalities leading to cell cycle deregulation, a functional mitotic checkpoint is essential to prevent mitotic catastrophe and tumor cell death. Here, we identify the RNA-binding protein HNRNPH1 as a key post-transcriptional modulator of G2/M checkpoint-associated genes in GBM. HNRNPH1 is overexpressed in malignant cells, especially in the neural- and oligodendrocyte-progenitor-like state, and its expression levels are higher in non-hypoxic regions of the tumor. Knocking out HNRNPH1 causes aberrant splicing and downregulation of several genes involved in cell division. These molecular alterations are associated with G2/M cell cycle arrest, reduced cell proliferation, abnormal cell morphology, and increased nuclear fragmentation. Silencing HNRNPH1 in vivo inhibits the tumor growth of patient-derived GBM cell-originated intracranial xenografts and has significant survival benefits. Together, our results show the critical importance of HNRNPH1 in cell cycle progression and tumor growth, potentially impacting the development of novel strategies to treat GBM.

Indexed as

Brain NeoplasmsGenes, cdcGlioblastomaHeterogeneous-Nuclear Ribonucleoprotein Group F-HRNA SplicingAnimalsCell CycleCell Line, TumorCell ProliferationDisease ProgressionG2 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansMiceHeterogeneous-Nuclear Ribonucleoprotein Group F-H

Identifiers

PMID41872153
PMCPMC13039110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.